Respiratory Medicine 2002: Vol 96 Index

17 Pages·2002·3.6 MB·English

MEDICINE
Index
Volume 96, 2002
ELSEVIER SCIENCE LTD
Copyright © 2002 Elsevier Science Ltd
ALL RIGHTS RESERVED
No part of this volume may be reproduced in any form,
by photostat, microfilm, or any other means, without
written permission from the publishers
respiratoryMEDICINE
Index to Volume 96
99mTc-DTPA, kinetics of lung clearance in smoking pa- Amsellem, C. 244
tients with sarcoidosis compared to healthy smokers 31 Amygdalou, A. 268, 499
Anderson, R. 582
xl-anti-trypsin phenotypes, deficient: influence on clini-
Andersson, F. 700
cal characteristics and severity of asthma in adults 186
Andersson, |. 944
Accuhaler “, salmeterol, versus eformoterol Turboha-
Andersson. M. 24
ler“ with symptomatic asthma, cost effectiveness 250
Ando, M. 18
adenose deaminase 2 (ADA?) activity in adults: useful-
Angus, R. 963
ness for the diagnosis of pulmonary tuberculosis 607
Ansola, P. 812
adenosine deaminase activity in bron hoalveolar lavage in
Anthony, R. E. 31
Turkish patients with smear negative pulmonary tu-
Argyropoulou, P. 594
berculosis 536
Arimura, K. 817
adenosine deaminase activity in sputum, diagnostic value
Arseven,O . 515
in pulmonary tuberculosis 632
Arshad, S. H. 163
Agusti, A.G. N. 193
Arvidsson, M. 1040
Ahlstedt, S. 95
Ailani, R 805 assisted ventilation, lack of additional effect adjunct of to
pulmonary rehabilitation in mild COPD patients 359
Ailani, R. K. 805
asthma: a proposal for a practical treatment guideline
Airmax'™: bronchodilating effects of salbutamol from a
novel inhaler 493 designed for the initial two hours of the management
:delivery of formoterol from a novel multi-dose inha- of patients with acute severe asthma and COPD using
ler 397 the principles of evidence-based medicine 659
:effects of 4-week treatment with low-dose budeso- rand asthma-like disorder: a 5-year follow-up study
1040
nide (100 tty BID) from a novel inhaler and from a con-
ventional inhaler on bronchial hyper-responsiveness, :and wheezing illnesses, prevalence amongst |0-year-
lung function and symptoms on patients with mild old schoolchildren 163
asthma 542 ‘applying evidence and theory to guide clinical decision
slung deposition of budesonide 389 making — implications for asthma management 567
:salbutamol and budesonide, delivery from a novel assessment of severity and treatment by GPs in Bel-
multi-dose inhaler 404 gium 170
Akahori, 469 :barriers in the management of asthma and attitudes
Akkaya, E. 519 towards complementary medicine 835
Al-Attia, H. M. 846 :blood eosinophil counts for the prediction of the se-
Aldons, P. M. 862 verity of exercise-induced bronchspasm 120
Aldrich,T .K . 984 :comparison of second controller medications in addi-
Aldridge, R. E. 950 tion to inhaled corticosteroid in patients with moder-
Alexandrakis, M. G. 553 ate asthma 322
Alimchandani, A. 805 ‘comparison of two budesonide powder inhalers,
Allen, M. 963 Easyhaler “ and Turbuhaler “, in steroid-nave asth-
allergen, inhaled: ambient level of NO augments the in- matic patients 599
flammatory response to in asthmatics 907 :control and differences in management practices
allergen avoidance effect of, lung function predictors in across seven European countries 142
infants at high risk of atopy: 230 :differences in trigger factors and symptoms between
allergen sensitization and allergen exposure in Greenlan- patients with asthma-like symptoms and patients
der Inuit residing in Denmark and Greenland 736 with asthma: development of a basis for a question-
alpha-l-antitrypsin deficiency: smoking, decline in lung naire 305
function and implications for therapeutic trials 872 :dyspnea, respiratory function and sputum profile in
Alvarez-Sala, J. L. 487 asthmatic patients during exacerbations 745
Ambrosino, N. 312, 359 :effect of deep inhalations after a bronchial methacho-
Amir,G . 890 line provocation in asthmatic and non-asthmatic pa-
amoxicillin/clavanulate: telithromycin is as effective in tients 477
acute exacerbations of chronic obstructive pulmonary :effect of ozone on bronchial mucosal inflammation in
disease 862 asthmatic and healthy patients 352
:effects of 4-week treatment with low-dose budeso- ‘severity, allergy and lung function during young mid-
nide (100 tty BID) from a novel inhaler Airmax'™ and dle life in subjects with asthma in childhood 716
from a conventional inhaler on bronchial hyper-re- ‘short-term effectivieness of an asthma educational
sponsiveness, lung function and symptoms on patients programme: results of a randomized controlled trial
with mild asthma 542 993
:effects of regular inhaled formoterol and budesonide :symptomatic: attendance and prescribing in general
on preformed Th-2 cytokines in mild asthmatics 1021 practice 102
:evaluation of different inhaled combination therapies ‘treatment of acute severe asthma and chronic ob-
(EDICT): a randomised, double-blind comparison of structive pulmonary disease in
Seretide '™ (50/250 jg bd) Diskus" vs. formoterol Danish hospitals: do national recommendations improve
and budesonide (800 1g bd) given concurrently (both on the quality of the treatment? 653
via Turbuhaler’) with moderate- to-severe asthma ‘treatment with herbal medicine T]-96: a randomized
85! controlled trial 469
-evaluation of long-term efficiency of an asthma educa- :up-regulation of heme oxygenase-| in alveolar macro-
tion programme in an out-patient clinic 519 phages of newly- diagnosed asthmatics 418
exhaled nitric oxide, short-term variability in young asthma, allergic: is the increase in bronchial responsive-
male patients with mild asthma in healthy subjects 895 ness or FEVI shortly after cessation of [}2-agonists re-
high prevalence of obesity in asthmatic patients on flecting a real deterioration of the disease? A
sick leave 642 comparison between short-acting and long-acting
‘incidence rates and risk factors for asthma among (}2-agonists 155
schoolchildren: a 2-year follow-up 1006 asthma, childhood: HPA-axis effects of nebulised flutica-
‘inflammatory marker serum eosinophil cationic pro- sone propionate compared with oral prednisolone in
tein (ECP) compared with PEF as a tool to decide in- 625
haled corticosteroid dose in asthmatic patients 95 asthma, occupational, flour-induced, diagnosis in a cross-
:influence of deficient xl-anti-trypsin phenotypes on sectional study 236
clinical characteristics and severity in adults 186 asthma, symptomatic: eformoterol Turbohaler “ versus
‘investigative bronchoscopy and endobronchial biopsy salmeterol Accuhaler “, cost effectiveness 250
is well tolerated in hyperreactive asthma patients 466 atopy: lung function predictors in infants at high risk of:
:natural allergen exposure does not diminish the sensi- effect of allergen avoidance 230
tivity of cytokine production to glucocorticosteroids :serum eosinophil cationic protein (S-ECP) in a popula-
in blood cells of seasonal allergic asthma and rhinitis tion with low prevalence of 525
927 Aubier, M. 862
:nitric oxide analysis applied to patients with COPD, Aziz, |. 548
allergic asthma and allergic rhinitis 24
:nitrous oxide: ambient level augments the inflamma- (32-agonists: is the increase in bronchial responsiveness
tory response to inhaled allergen in asthmatics 907 or FEVI shortly after cessation reflecting a real dete-
:pilot study examining the relationship between stress rioration of allergic asthma? A comparison between
and serum cortisol concentrations in women with short-acting and long-acting ?(}2-agonists 155
asthma 823 Baccheschi,J . 110
:prevalence and risk for asthma and chronic bronchitis Bach, P. B. 280
in the capitals Helsinki, Stockholm and Tallinn 759 Bachour, A. 586
:prevalence with allergic rhinitis and eczema among Backer, V. 736
university students in Bangkok 34 Bailey,W .C . 444
:prospective, placebo-controlled trial of 5 vs I0 days of Bakir, K. 275
oral prednisolone in acute adult asthma 950 Bakke, P. S. 424
:relationship between patient and disease characteris- Balachandran, D. !78
tics, and health-related quality of life in adults with Balcells, E. 186
asthma 450 BALF N-acetylglucosaminidase and {3-galactosidase ac-
:relative therapeutic index between inhaled formoter- tivities in idiopathic pulmonary fibrosis 75]
ol and salbutamol in asthma patients 412 Banno, S. 770
‘rhinitis increases the risk for adult-onset asthma — a Barbe, F. 193
Swedish population-based case-control study (MAF- Barcelo, A. 193
study) 635 Barck, C. 907
‘safety, tolerability and acceptability of two dry pow- Barnacle, H. 625
der inhalers in the administration of budesonide in Barnes, N. 963
steroid-treated asthmatic patients 221 Barrett-Connor, E. 796
Barrientos, A. 487 Brudin, L. 115
Barta, S.K. 375 BrugnamGi. ,99 3
Beder, S. 536 Buckley, J. 805
Behrakis, P. 268 budesonide : and salbutamol, delivery from a novel multi-
Behrakis, P. K. 499 dose inhaler Airmax’ 404
Bellia,V .8 81 slung deposition from the novel dry powder inhaler
Bende, M. 731 Airmax'™ 389
Benotti, P. N. 672 budesonide (100 tty BID) low-dose: effects of 4-week
Bensi,G . 881 treatment from a novel inhaler Airmax'™ and from a
Benvenuti, A. 236 conventional inhaler on bronchial hyper-responsive-
Berkman, N. 890 ness, lung function and symptoms on patients with
Bianchi Martini, L. 236 mild asthma 542
Bianchi, L. 312, 359 budesonide (800 tig bd) and formoterol given concur-
Bianchi, R. 745 rently (both via Turbuhaler’™) vs evaluation of differ-
Bianco, S. 881 ent inhaled combination therapies (EDICT): a
Bienfait-Beuzon, C. 862 randomised, double-blind comparison of Seretide
Biesterfeld, S. 87 (50/250 j1g bd) Diskus’ with moderate- to-severe
Bijl-Hofland, |. D. 155 asthma 85
biopsy, closed pleural needle: predicting diagnostic yield budesonide administration: safety, tolerability and ac-
by examining pleural fluid 890 ceptability of two dry powder inhalers in steroid-trea-
biopsy, endobronchial, and investigative bronchoscopy ted asthmatic patients 221
is well tolerated in hyperreactive asthma patients budesonide and formoterol, effects of regular inhalation
466 on preformed Th-2 cytokines in mild asthmatics 1021
Bjarneman, P. 305 budesonide or theophylline: effect of long-term treat-
Bjermer, L. 796 ment on lung function, airway reactivity and asthma
Bjorkstén, B. 525 symptoms 432
Blomberg, A. 352 budesonide powder inhalers, Easyhaler ~ and Turbuha-
Blom-Bulow, B. 317 ler", comparison in steroid-nave asthmatic patients 599
Bocskei, C. 412 BusseW., W . 293
Boman, G. 525 Bylin,G . 907
Borg, S. 700 Byrd, R. P. 672
Bortesi, M. L. 215
Bouros, D. 553 Caglayan, B. 677
Brackel, H. J. L. 976 Cakan, M.D. A. 506
Bradvik, |. 317 Califano, C. 790
Bratel,T .9 34 Calisir, H.C. 322
Breuer, R. 890 Cantini, L. 784
Brianti, M. 215 capsaicin inhalation test for identification of sensory
Broberg, P. 927 hyperreactivity 731
bronchial hyperreactivity, role of TNF-% and its 55 and 75 Carldstedt, I. 81
kDa receptors 262 Carlucci, P. 137
bronchial mucosal inflammation: effect of ozone in asth- Carrara, M. 236
matic and healthy patients 352 Carty, S. M. 31
bronchiectasis: relationship between psychological well- Casanova, S. 137
being and lung health status in patients with 686 Casciola, G. 993
bronchiolitis obliteran organizing pneumonia in cancer: a Castagna, F. 137, 439
case series 280 Cazzola, M. 137, 439, 790
bronchitis, chronic: quality of life in acute exacerbation: Centanni, S. 137, 439
results from a German population study 39 cephalosporin-resistant pneumococcal pneumonia: does
bronchitis: prevalence and risk for asthma and chronic it affect outcome? 805
bronchitis in the capitals Helsinki, Stockholm and Tal- Ceyhan, B. B. 61
linn 759 Chambe, M.-T. 244
bronchodilator response, expression: comparison of four Chhabra, S. K. 6ll
indices 6ll Choi, |. S. 120, 150
bronchoscopy, investigative, and endobronchial biopsy is cholecystectomy, laparoscopic, respiratory system me-
well tolerated in hyperreactive asthma patients 466 chanics during 268
RESPIRATORY MEDICINE
Chovan, L. 851 ‘tumor necrosis factor — alpha serum levels, weight
Christensen, G. 901 loss and tissue oxygenation in 594
Christensen, L. K. 653, 659 :urinary desmosine excretion in acute exacerbations
Christian, J. 31 of COPD: a preliminary report I10
Christion, R. D. 450 :why developed by so few smokers? 615
chronic obstructive pulmonary disease: a proposal for a Chuchalin, A. 851
practical treatment guideline designed for the initial Chung, F. 963
two hours of the management of patients with acute Chung, K. F. 81
severe asthma and COPD using the principles of evi- Cioppa, G. D. 1021
dence-based medicine 659 Clark, D. A. 389
‘acute effects of higher than customary doses of sal- Clausen, J. 796
meterol and salbutamol with acute exacerbation of Clini, E. 312
790 clonezapam combined with nasal CPAP, efficacy on poly-
:addition of an extra dose of salmeterol Diskus“ to somnographic variables in high leg motor activity in
conventional dose of salmeterol Diskus " in patients sleep apnea hypopnea patients 693
with COPD 439 Cloosterman, S.G. M. 155
:cost-benefit and cost-effectiveness analysis of self- Cockeran, R. 582
management in patients with COPD — a |-year fol- Cole, P. 582
low-up randomised, controlled trial 424 Cole, P. |. 686
:costs of exacerbations 700 Colledge, J. 397, 404
:does inspiratory behaviour affect the efficiency of complementary medicine, barriers in the management
non-invasive ventilation? 709 of asthma and attitudes towards 835
:effect of oxolamine on cough sensitivity in COPD pa- Compte, L. 777
tients (SR) 6l Conde, M. B. 607
:effects of formoterol (Oxis “ Turbuhaler" ) and ipra- Connett, J. E. 444
tropium on exercise capacity in patients with 559 Constantopoulos, S. H. 499
:frequency of deep venous thrombosis and pulmonary Cooper, D. 872
embolus in acute exacerbation 515 Corless, J. A. 59
‘individual dietary intervention in patients with COPD Coronel, F. 487
during multidisciplinary rehabilitation 330 Corris, P. 963
‘lack of additional effect of adjunct of assisted ventila- Corris, P. A. 67
tion to pulmonary rehabilitation in mild COPD pa- corticosteroid, inhaled, comparison of second controller
tients 359 medications in addition to in patients with moderate
:long-term oxygen therapy and quality of life in elderly asthma 322
patients hospitalised due to exacerbation of 944 Costello, R. W. 823
‘nitric oxide analysis applied to patients with COPD, cough sensitivity: effect of oxolamine in COPD patients
allergic asthma and allergic rhinitis 24 (SR) 61
:nitric oxide, exhaled, and exercise tolerance in severe Crawford, A. 375
COPD patients 312 Creemers, J. P.H. M. 197
:normocapnia during nIPPV in chronic hypercapnic Crohn's disease and ulcerative colitis, activity related in-
COPD reduces subsequent spontaneous PaCO, 572 crease in exhaled nitric oxide: a manifestation of sys-
:oxitropium bromide, theophylline and their combina- temic involvement? 530
tions in COPD patients: a double-blind, randomized Cseh, K. 262
multicentre study (BREATH trial) 881 Cserhati, E. 262
:oxitropium bromide: bronchodilating effect in heart Cuhadaroglu,© . 515
disease patients with exacerbations of COPD: dou- Curbow, B. A. 823
ble-blind, randomized, controlled study 137 Curradi, F. 993
:quality of life and functional parameters in patients cystic fibrosis: demographic transition of the Swedish
with COPD: an update 373 community — results of modern care 681
‘safety of sputum induction in moderate-to-severe expression of MUCSAC and MUCSB mucins in nor-
482 mal and cystic fibrosis lungs 81
‘telithromycin is as effective as amoxicillin/clavanulate expression of Fas and CD40 and induction of
in acute exacerbations of 862 apoptosis in human cystic fibrosis airway epithelial
‘treatment of acute severe asthma and COPD in Dan- cells 244
ish hospitals: do national recommendations improve :peripheral decrease and pulmonary homing of
on the quality of the treatment? 653 CD4+CD45RO+ helper memoryT cells 87
D’Amato, G. 790 :respiratory function and sputum profile in asthmatic
D’Amato, M. 790 patients during exacerbations 745
Dahl, R. 432 :perception: relationship with airway inflammatory
Dakin, K. S. 31 markers 150
Dalavanga,Y . A. 499 Easyhaler “ and Turbuhaler “, budesonide powder inha-
Daley-Yates, P. 625 lers, comparison in steroid- nave asthmatic patients
Dalton, M. 990 599
Davies, P. D.O. 59 Eaton,T . 204
De Backer, W. A. 95 Ebeo, C.T . 672
De Carvalho Kallas, F. 51! Ece,T . 515
De Fatima Pereira, M. 607 eczema: prevalence with allergic rhinitis and asthma
de la Roza, C. 186 among university students in Bangkok 34
De Maertelaer, V. 693 Edlund,T . 209
De Vuyst, P. 170 eformoterol Turbohaler “ versus salmeterol Accuhaler''
De, S. 6ll with symptomatic asthma, cost effectiveness 250
decision making, clinical, applying evidence and theory — Efthimiou, J. 625
implications for asthma management 567 Eide, G. E. 1033
deep venous thrombosis and pulmonary embolus, fre- Eimoto,T .7 70
quency in acute exacerbation of chronic obstructive Ekroos, H. 895
pulmonary disease 515 El Khawand, C. 709
Dekhuijzen, P. N. R. 197 El-Abassi, R. N. 846
Del Borello, P. 215 Elborn, J. S. 841
Delaney, D. 178 Ellidokus, M. D. H. 506
Delaunois, L. 709 Elmaghraby, Z. 672
Delibalta, M. 536 Emtner, M. 24
Demedts, M. 979 end-expiratory pressure: evaluation by multiple linear
Dennis, P. M. 31 regression and Fourier analysis in humans 499
Deshpande, K. S. 984 Engstrom, C.-P. 330
desmosine excretion, urinary, in acute exacerbations of Enkaya, |. 275
COPD: a preliminary report I10 Enright, P. L. 444
Devadason, S.G.990 eosinophil cationic protein (ECP) compared with PEF as
Di Marco, F. 137, 439 a tool to decide inhaled corticosteroid dose in asth-
Di Perna, F. 790 matic patients 95
diabetes, type |: lung function abnormalities in children eosinophilic airway inflammation as an underlying me-
with 976 chanism of undiagnosed prolonged cough in primary
dialysis patients, chronic, pulmonary diffusing capacity in healthcare patients 52
487 Erbag, B. 275
Diaz,G . |4 Erelel, M. 515
dietary intervention, individual, in patients with COPD Erickson, S. R. 450
during multidisciplinary rehabilitation 330 Ericsson, A. 700
DiGiovine, B. 805 Eryimaz,T .6 32
Dilmag, A. 632 Evander, E. 317
Dinkelaker, A. 1026 Evenepoel, P. 530
Djukanovich, R. 7 Everden, P. 250
Doll, H. 39 exercise capacity in patients with chronic obstructive
Domenech, R. 777 pulmonary disease, effects of formoterol (Oxis “ Tur-
Donner,C . F. 95 buhaler “) and ipratropium on 559
Donovan, K. J. 129 exercise tolerance and exhaled nitric oxide in severe
dry powder inhaler design, formulation and perfor- COPD patients 312
mance, evaluation 283 exercise-induced bronchspasm in asthma: blood eosino-
Du Bois, R. M. 67 phil counts for the prediction of the severity of |20
Duncan, C. 625 Eynott, P.R. 8I
Duprat-Lomon, I. 39
Duranti, R. 745 Faghihim M. 382
Durieu, |. 244 Farrell, D. J. 259
dyspnoea: do steroids interfere in sensation? 5]| Feldman, C. 582
RESPIRATORY MEDICINE
Fenn, M. 163 glucocorticosteroids: natural allergen exposure does not
fibrosis, idiopathic pulmonary, BALF N-acetylglucosami- diminish the sensitivity of cytokine production to glu-
nidase and /}-galactosidase activities in 75| cocorticosteroids in blood cells of seasonal allergic
Fidan, A. 677 asthma and rhinitis 927
Filho, J.T. SII Goldman, J. M. 259
Finsnes, F. 901 Golshan, M. 382
Fiorenza, D. Il0 Gorostiza, A. 812
Fisher, D. 337 Gozu, A. Akkalyoncu, B. 632
Fitzgerald, S. T.8 23 Grassi,V . 881
Fleischer, W. 1026 Grazzini, M. 373
Flood,Y . 625 Green, L. 625
flour-induced occupational asthma, diagnosis in a cross- Greenstone, M. A. 548
sectional study 236 Greiff, L. 927
fluticasone propionate, nebulised, HPA-axis effects Grey-Amante, P. 39
compared with oral prednisolone in childhood Groneberg, D. A. 8I
asthma 625 Grongerg, 330
Foglio, K. 312, 359 Guariglia, A. 215
Fogue, L. 14 Gulsvik, A. 1033
Folgering, H. Th. M. 155 Gupta, R. 6ll, 835
Foresi, A. 881 Gustafsson, P. 957
formoterol: delivery from a novel multi-dose inhaler Air- Gustafsson, P. M. 716
max'"' 397
‘inhaled: relative therapeutic index between and sal- Haahtela,T . 52, 918
butamol in asthma patients 412 Halasz, A. 262
:possibilities to enhance the peripheral lung deposition Halldén, G. 907
of the inhaled liposome corticosteroids 999 Halman, L. J. 450
formoterol (Oxis“ Turbuhaler") and ipratropium: ef- Halme, M. 466
fects on exercise capacity in patients with chronic ob- Halmerbauer,G . 230
structive pulmonary disease 559 Hamalainen, K. M. 221
formoterol and budesonide (800 jig bd) given concur- Hamm, H. 572
rently (both via Turbuhaler™) vs. Seretide '™ (50/250 Hancock, E. |, 7
ug bd) Diskus’ with moderate-to-severe asthma, Hancox, M. 842
evaluation of different inhaled combinationtherapies Hansell, D. M. 686
(EDICT): a randomised, double-blind comparison of Hansen, E. F. 653
85| Hansen, L. S. 653, 659
formoterol and budesonide, effects of regular inhalation Hansson, L. 559, 927
on preformed Th-2 cytokines in mild asthmatics 1021 Harff, G. A. 197
Forsberg, P. II5 Harju,T . 418
Frew, A. J. 352, 542 Hatem, C. 984
Frischer,T . 230 Hatzizisi, O. 594
Fujita, J. 770 Hausler, M. 87
Fukunaga, H. 817 Hedenstrom, H. 24
Heide, A. 1026
Gaber K. A. 259 Heimann, G. 87
Galdiz,| .B . 812 Helleday, R. 352
Gallefosse, F. 424 Hellgren, J. 635
Gamez,C . 487 heme oxygenase-l, up-regulation in alveolar macro-
Gandola, L.95 phages of newly-diagnosed asthmatics 418
Ganotakis, E. 553 hemoptysis: a retrospective analysis of 108 cases 677
Garrod, R. 725 Hennings, E. 572
Gartner, C. 230 hepatocyte growth factor serum levels: and exhaled
Ge, X. 829 breath condensate in pneumonia II5
gender differences in the impact of adolescent smoking herbal medicine T]-96 treatment of asthma: a rando-
on lung function and respiratory symptoms 796 mized controlled trial 469
Gessner, C. 75l Hermansson, B. A. 635
Gigliotti, F. 373 Herrala, J. 586,999
Herrero, J. A. 487 Ja nsson, S.-A. 700
Hertog, M.G. L. 389, 542 Ja rdi, R. 186
Hidalgo, }. 805 J
Hirst, P. 1026 J
Hirst, P. H. 389 Jw ie, H.F 1033
histamine challenge, associated subject discomfort in a Je t spacer, a new HFA-134a propellant in the adminis-
population study 990 tration of inhaled BDP via, controlled clinical trial vs
Ho,} . L. 607 the conventional CFC 784
veanen, M. 24 Jiménez, D. 14
Holgate, S. 1021 Jogi, \r. 525
Holgate, S.T. 95 Johan, A. 46l
Holmen, J. 796 Johansson, A. 731
Holmen,T . L. 796 Johansson, K. 944
Holmkvist,T . 24 John, M. 126
Hopkinson, L. 950 Jones, A. M. 950
Hrabec, E. 127 Jones, P.W. 567, 686
Hrabec, Z. 127 Jones, S. 397, 404
Hutchinson, J. 250 Jonsson, A.-C. 700
Hutchison, D.C. S. 872 Jonsson, L. M. 209
hydrogen peroxide: an efficient and reproducible meth- Juhasz,G . 412
od for measuring in exhaled condensate 197 Jung, K. 126
hydrogen peroxide and pneumolysin, effects alone and in
combination on human ciliated epithelium tro 582 Kaewsomboon, S. 34
hyperreactivity, sensory, capsaicin inhalation test for Kallman, S. 957
identification of 731 Karaca, L. 536
hyperthyroidism and pulmonary hypertension 215 Karakurt, S. 6l
Karjalainen, |. 895
ladarola, P. 110 Karnak, D. 536
infants at high risk of atopy, lung function predictors: ef- Karwam M. 984
fect of allergen avoidance 230 Kastelik, J. A. 548
Inoue, K. 817 Kattaa, H. A. 846
interferon-yinhibits eosinophilic airway inflammation Kawabato, M. 817
and leukotriene antagonism reduces the generation Kayacan,O . 536
of endothelin-! 901 Kehrt, R.955
interleukin 6 (IL 6), tumor necrosis factor-x (TNF-), and Kelly, F. J. 352
their soluble receptors, serum levels in coal workers’ Kelly, M.G . 841
pneumoconiosis 829 Kempenaers, C. 693
internet: survey of public knowledge about tuberculosis Kerstjens, H. A. M. 559
(SR) 59 Keski-Karhu,} . 221
intracellular markers, identification in induced sputum Kilinc,O . 506
and bronchoalveolar lavage samples in patients with Kinnula,V . L. 418
respiratory disorders and healthy persons 918 Kirking, D. M. 450
Inuit: allergen sensitization and allergen exposure in Kiviloog, J. 759
Greenlander Inuit residing in Denmark and Greenland Kiviniemi, P. 52
736 Kjellman, B. 716
ipratropium and formoterol (Oxis“ Turbuhaler“): ef- Klaue, S.955
fects on exercise capacity in patients with chronic ob- Knox, A. 963
structive pulmonary disease 559 Koek,G . H. 530
Iran: indoor women jobs and pulmonary risks in rural Koh,Y . |. 120
areas of Isfahan 389 Kohonen-Jalonen, P. 52
lriberri, M. 812 Korsgaard, J. 344, 736
Koskela,T . 599
Jaca,C . 812 Koskinen, M.O. 999
Jamart, J. 709 Kotasova, 784
Jang, A.-S. 150 Kovacs, M. 262
Janson,C . 525 Koziel, H. 178
RESPIRATORY MEDICINE
Krishna, M. T.3 52 Lundback, B. 700, 759, 1006
Kritski, A. L. 607 lung abcess in adults: clinical comparison of immuno-
Kurukulaaratchy, R. J. 163 compromised to non-immunocompromised patients
Kvetan, V. 984 178
Kyriakou, D. S. 553 lung cancer patients with reactive thrombocytosis, ser-
Kyriazis,G . 594 um proinflammatory cytokines and its relationship to
clinical parameters in 553
Lagerstrand, L. 934 lung cancer, bronchoscopic diagnosis: cytological exami-
Laitinen, L. A. 466, 759, 895 nation of the whole endobronchial brush 259
Langhammer, A. 796 lung disease: role of small airways 67
Langley, S. J. 542 lung function abnormalities in children with type | dia-
Langmack, E. L. 482 betes 976
Lanini, B. 745 lung function predictors in infants at high risk of atopy:
Lannefors, L. 681 effect of allergen avoidance 230
Lanquart,J . P. 693 lung function: relationship to ventilation-perfused in-
Laopodis,V . 268 equality and extent of emphysema as assessed by
Lapa e Silva, J. R. 607 high-resolution computed tomography 934
Larsen, B. B. 432 Lupi, A. 110
Larsson, K. 477, 642, 759 Lusuardi, M. 95
Larsson, L.95 Lyberg,T .9 01
Larsson, P. 412 lymphangioleiomyomatosis: a review of the literature |
Larsson, S. 330, 927,944 lymphangioleiomyomatosis: and tuberous sclerosis 7
Larusdottir, H. 317
Laube, B. L. 823 Maasilta, P. 586
Lauren, L.C. 653, 659 McConnell, A. K. 129
Lavie, P. 337 Macfarlane, J.T. 31
Leak, A. 862 McKeith, D. D. 86
Lenney,W . 625 Macian, V. 777
Leroy, B. 862 Maggi, E. 851
leukotriene antagonism reduces the generation of en- MAGhaler dry powder inhaler, lung deposition of salbu-
dothelin-! and interferon-y inhibits eosinophilic air- tamol in healthy human subjects from the 1026
way inflammation 901 Magyar, P. 262
Li, |.990 Maier,W . C. 142
Liang, D. 829 Mak, K.-H. 461
Liesker, J. J.W. 559 Malhotra, A. 337
Light, R. W. 14 Malik, S. 1026
Lim, S. 81 Malinen, A. 599
Lim, W. S. 31 Mandragos, C. 499
Linden, M. 927 Mansharamani, N. 178
Lindgren, A. 681 Marabini, A. 993
Lindqvist, A. 46 Marandi, M. M. 382
Linstow, M. L. 736 Marani,G . 215
Liu,G . 829 Margantinis,G . 553
Llompart, E. 193 Marinho, S. R. 607
Lloyd, A. 250 Marklund, S. L. 209
Lofdahl, C.-G. 927 Marsico, S. A. 790
Loit, H.-M. 759 Martin, R. J. 482
London Chest Activity of Daily Living: evaluation of the Martinez Garcia, M. A. 777
reliability and sensitivity 725 Martinez,J . A. B. Sil
Lorenz, J. 39 Marvisi, M. 215
lower respiratory tract infections: intensified microbio- Matera, M.G . 439, 790
logical investigations in adult patients 344 Matsuyama,W. 817
Lowhagen, O. 95, 305, 731, 1040 Matthews, S. 163
Lui,J .6 72 Matthys, H. 572
Luisetti, M. 110 Mavrofridis, E. 594
Lundahl,| .9 07 Meren, M. 759